Factory 99% Eribulin Powder CAS 253128-41-5 Chemical Intermediate Eribulin

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A924
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Eribulin
• CAS: 253128-41-5
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Eribulin
Appearance	White Powder
CAS NO.	253128-41-5
Storage	Keep in a cool, dry, dark location

 

Eribulin is a medication used in the treatment of certain types of cancer. It is a microtubule dynamics inhibitor, derived from a natural product found in marine sponges, and belongs to a class of drugs known as chemotherapeutics.

 

1. Metastatic Breast Cancer: Eribulin is approved for the treatment of patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease. It is often used as a later-line therapy for patients whose disease has progressed despite other treatments.

2. Soft Tissue Sarcoma: Eribulin is also indicated for the treatment of adult patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. It provides a therapeutic option for patients with this rare and aggressive form of soft tissue cancer.

3. Other Cancers: While its primary indications are in breast cancer and soft tissue sarcoma, clinical trials are ongoing to explore the potential use of eribulin in other types of cancers, such as bladder cancer, prostate cancer, pancreatic cancer, head and neck cancer, and non-small cell lung cancer.

1. Microtubule Dynamics Inhibition: The primary mechanism of action of eribulin is to inhibit microtubule dynamics, a critical process involved in cell division. By interfering with the formation and function of microtubules, eribulin disrupts the cell cycle and prevents cancer cells from dividing and proliferating.

2. Antimitotic Activity: By blocking the progression of cancer cells through the cell cycle, specifically at the G2/M phase, eribulin induces cell cycle arrest and ultimately leads to cell death. This antimitotic effect is the basis for its antitumor activity.

3. Anti-angiogenic Effect: In addition to its direct effects on cancer cells, eribulin has been shown to exhibit anti-angiogenic properties. This means it can inhibit the formation of new blood vessels that supply tumors with oxygen and nutrients, thereby limiting tumor growth and spread.